These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 27158016)

  • 1. PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism.
    Prasad V; Ambrosini V; Alavi A; Fanti S; Baum RP
    PET Clin; 2007 Jul; 2(3):351-75. PubMed ID: 27158016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism.
    Prasad V; Ambrosini V; Alavi A; Fanti S; Baum RP
    PET Clin; 2008 Jul; 3(3):355-79. PubMed ID: 27156666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.
    Oh S; Prasad V; Lee DS; Baum RP
    Int J Mol Imaging; 2011; 2011():524130. PubMed ID: 22121482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
    Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
    Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of neuroendocrine tumors.
    Sundin A
    Expert Opin Med Diagn; 2012 Sep; 6(5):473-83. PubMed ID: 23480811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
    Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
    Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J
    Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead.
    Sundin A; Rockall A
    Neuroendocrinology; 2012; 96(4):261-71. PubMed ID: 22907438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging of neuroendocrine tumors.
    Öberg K
    Expert Rev Endocrinol Metab; 2008 Nov; 3(6):739-749. PubMed ID: 30764063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy.
    Signore A; Lauri C; Auletta S; Varani M; Onofrio L; Glaudemans AWJM; Panzuto F; Marchetti P
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with
    Bozkurt MF; Virgolini I; Balogova S; Beheshti M; Rubello D; Decristoforo C; Ambrosini V; Kjaer A; Delgado-Bolton R; Kunikowska J; Oyen WJG; Chiti A; Giammarile F; Sundin A; Fanti S
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2150-2151. PubMed ID: 28856372
    [No Abstract]   [Full Text] [Related]  

  • 15. Correction to: Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
    Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Lococo F; Margaritora S; Pescarmona E; Rindi G
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4289. PubMed ID: 35699752
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnostic and prognostic value of
    Saponjski J; Macut D; Petrovic N; Ognjanovic S; Popovic B; Bukumiric Z; Sobic Saranovic D
    Arch Med Sci; 2023; 19(6):1753-1759. PubMed ID: 38058718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Value of (68)Ga-DOTATATE PET/CT in Liver Metastases of Neuroendocrine Tumours of Unknown Origin.
    Tan TH; Lee BN; Hassan SZ
    Nucl Med Mol Imaging; 2014 Sep; 48(3):212-5. PubMed ID: 25177378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease.
    Oh JR; Kulkarni H; Carreras C; Schalch G; Min JJ; Baum RP
    Nucl Med Mol Imaging; 2012 Jun; 46(2):129-33. PubMed ID: 24900047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear medicine imaging of neuroendocrine tumours.
    Al-Nahhas A
    Clin Med (Lond); 2012 Aug; 12(4):377-80. PubMed ID: 22930887
    [No Abstract]   [Full Text] [Related]  

  • 20. Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management.
    Naji M; Hodolic M; El-Refai S; Khan S; Marzola MC; Rubello D; Al-Nahhas A
    J Endocrinol Invest; 2010 Jan; 33(1):54-60. PubMed ID: 19820296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.